-
Mashup Score: 6Pan-Cancer Comparative and Integrative Analyses of Driver Alterations Using Japanese and International Genomic Databases - 2 day(s) ago
A multi-cohort, pan-cancer analysis uncovered racial disparities in cancer genomes between Asian and White populations and elucidated pairwise relationships of driver alterations, providing valuable resources for precision medicine in cancer.
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4
PURPOSE Many patients with actionable driver oncogenes (ADOs) are never identified and thus never receive targeted treatment. This study evaluated the economic impact and the potential life-years gained (LYG) that can be attributed to the extent of next-generation sequencing (NGS) testing in the United States compared with single-gene testing (SGT) in patients with metastatic nonsquamous non–small-cell lung cancer in the United States. METHODS A model was developed to evaluate incremental rates of SGT or NSG testing on the basis of LYG and cost per LYG. ADOs included for NGS included EGFR, ALK, ROS1, BRAF, RET, MET, and NTRK. SGT included EGFR and ALK. Assumptions were made for expected incidence of ADOs. Survival distributions were fit to published trial averages of median and 5-year overall survival. Treatment costs were estimated from drug cost averages. Reimbursement costs were based on data from the Center for Medicare and Medicaid Services. RESULTS Each incremental 10% increase i
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1
PURPOSE Clinical trials of novel and targeted agents increasingly require biomarkers for eligibility. Precision oncology continues to evolve, but challenges hamper broad use of molecular profiling (MP) that could increase the number of patients benefiting from targeted therapy. We implemented an integrated clinical genomics program (CGP), including a virtual Molecular Tumor Board (MTB), and examined its impact on MP use and impact on clinical trial accrual in a multisite regional-based cancer system with an emphasis on effects for isolated clinicians. METHODS We assessed MP and MTB use from 2010 to 2020 by practice location, physician experience, and patient characteristics. Use of MTB-recommended treatments was assessed. Clinical trial enrollment was evaluated for patients with MP versus MP and MTB review. RESULTS After CGP implementation, the number of physicians using MP and the number of MP tests increased ≥ 10-fold. The proportion of Hispanic patients with MP was the same as that
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4Implementation and Clinical Utility of an Integrated Academic-Community Regional Molecular Tumor Board - 2 day(s) ago
Purpose Precision oncology develops and implements evidence-based personalized therapies that are based on specific genetic targets within each tumor. However, a major challenge that remains is the provision of a standardized, up-to-date, and evidenced-based precision medicine initiative across a geographic region. Materials and Methods We developed a statewide molecular tumor board that integrates academic and community oncology practices. The Precision Medicine Molecular Tumor Board (PMMTB) has three components: a biweekly Web-based teleconference tumor board meeting provided as a free clinical service, an observational research registry, and a monthly journal club to establish and revise evidence-based guidelines for off-label therapies. The PMMTB allows for flexible and rapid implementation of treatment, uniformity in practice, and the ability to track outcomes. Results We describe the implementation of the PMMTB and its first year of activity. Seventy-seven patient cases were pres
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Reportable actionability versus pragmatic actionability: Implementing precision medicine at three large health systems. - 2 day(s) ago
6539 Background: Precision medicine (PM) molecular panel (MP) testing report actionable findings with associated targeted therapies (including immunotherapies). However, these actionable findings “reported actionability” by molecular testing companies are often not realized as “pragmatic actionability” in the real world setting. We explored the concordance among PM MP therapy recommendations and subsequent drug treatment orders by clinicians at Aurora Health Care (AHC), Henry Ford Health System (HFHS), and Hoag Memorial Hospital Presbyterian (HMHP). Methods: Structured clinical, genomic report data, and treatment orders were obtained from the Syapse database. At AHC, HFHS, and HMHP, we identified 996 MP reports from 748 patients who received testing between 2014 and 2018. Results: 713 MP reports had “reported actionable” (positive) treatment recommendations and a subsequent treatment order across all 3 health systems. 24.4% (174/713) of MP reports were followed by a treatment order tha
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Implementing Precision Medicine Programs and Clinical Trials in the Community-Based Oncology Practice: Barriers and Best Practices - 2 day(s) ago
There has been a rapid uptick in the pace of oncology precision medicine advancements over the past several decades as a result of increasingly sophisticated technology and the ability to study more patients through innovative trial designs. As more precision oncology approaches are developed, the need for precision medicine trials is increasing in the community setting, where most patients with cancer are treated. However, community-based practices, as well as some academic centers, may face unique barriers to implementing precision medicine programs and trials within their communities. Such challenges include understanding the tissue needs of molecular tests (e.g., tumor, blood), identifying which molecular tests are best used and when tissue should be tested, interpreting the test results and determining actionability, understanding the role of genetic counseling and/or follow-up testing, determining clinical trial eligibility, and assessing patient attitudes and financial concerns.
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Quantifying the Value of the Molecular Tumor Board: Discordance Recommendation Rate and Drug Cost Avoidance - 2 day(s) ago
PURPOSE Molecular tumor boards (MTBs) provide interventions that assist the patient’s primary oncologist’s interpretation and application of precision oncology and avoid clinical and financial toxicities of prescribing inappropriate targeted therapy. In this article, we describe a novel method for illustrating MTBs value and recommendation discordance rate and report associated drug cost avoidance data. METHODS From January 1, 2021, to December 31, 2021, patients assessed by our program’s MTB were retrospectively evaluated. Recommendation discordance was defined as any disagreement between MTB therapeutic recommendations and those provided in the next-generation sequencing vendor’s report. RESULTS In 2021, our program processed 1,119 next-generation sequencing orders via external vendors for 1,029 unique patients with a variety of solid tumor and hematologic malignancies. During this period, 962 patients were reviewed through our MTB process. MTB recommendation discordance rate was hig
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Program Guide – ASCO Meeting Program Guide - 2 day(s) ago
Suanna S. Bruinooge American Society of Clinical Oncology, Alexandria, VA American Society of Clinical Oncology, Alexandria, VA, Mayo Clinic, Scottsdale, AZ, City of Hope, Duarte, CA, Carol B. White & Associates, Evanston, IL, Research Advocacy Network, Naperville, IL, Stanford School of Medicine, Stanford, CA, Research Advocacy Network, Plano, TX, University of Michigan, Ann Arbor, MI Background: This survey of Targeted Agent and Profiling Utilization Registry (TAPUR) Study physicians examined use, a
Source: meetings.asco.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0
PURPOSE The TAPUR Study is a phase II basket trial that aims to identify signals of antitumor activity of commercially available targeted agents in patients with advanced cancers harboring genomic alterations known to be drug targets. Results in a cohort of patients with metastatic breast cancer (mBC) with high tumor mutational burden (HTMB) treated with pembrolizumab are reported. METHODS Patients with advanced mBC received standard doses of either 2 mg/kg or 200 mg infusions of pembrolizumab every 3 weeks. Simon’s two-stage design was used with a primary study end point of disease control (DC) defined as objective response or stable disease of at least 16 weeks duration. If two or more patients in stage I achieved DC, the cohort would enroll 18 additional patients in stage II. Secondary end points include progression-free survival (PFS), overall survival, and safety. RESULTS Twenty-eight patients were enrolled from October 2016 to July 2018. All patients’ tumors had HTMB ranging from
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1ClinicalTrials.gov - 2 day(s) ago
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Source: clinicaltrials.govCategories: General Medicine News, Hem/OncsTweet
Pan-cancer comparative and integrative analyses of driver alterations using Japanese and international genomic databases [Jan 26, 2024] @Sara_Horie @YukiSaito_MDPhD @kataoka_lab et al. @CD_AACR https://t.co/Z9DitwDhuH #PrecisionMedicine #globonc @NccriOfficial @NccCat